Clinical Trial Detail

NCT ID NCT02160041
Title BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Novartis Pharmaceuticals
Indications

hematologic cancer

Advanced Solid Tumor

Therapies

BGJ398

Age Groups: adult

Additional content available in CKB BOOST